Vaccines remain among the most consequential tools in modern public health, reducing morbidity and mortality for numerous infectious diseases. However, public discourse often substitutes authority, consensus language, and simplified messaging for scientific explanation. This essay argues that vaccines should be understood as imperfect, context-dependent risk-management tools rather than flawless interventions. It examines evidence regarding variable effectiveness, repeated-dose attenuation, immune imprinting, hyporesponsiveness in specific vaccine classes, natural immunity, and unresolved questions about non-specific effects. The analysis emphasizes the critical distinction between high-risk populations and the general healthy population, clarifies why scientific consensus is not proof, and explains why ongoing inquiry into potential harms, including controversial topics, remains a legitimate and necessary component of scientific progress. The objective is not vaccine rejection, but epistemic accuracy.
Introduction
Vaccines occupy a unique intersection of biology, medicine, and public policy. They are simultaneously biomedical interventions and population-level tools, designed not for individual optimization but for reducing aggregate risk. This dual role has consequences. In public communication, nuance is often sacrificed for clarity, and uncertainty is frequently misinterpreted as a sign of weakness or threat. Over time, this has fostered a cultural expectation that vaccines must be defended as perfect rather than understood as probabilistic tools operating within complex immune systems. Scientific literacy requires resisting this framing. No serious immunologist claims vaccines are universally optimal, uniformly effective, or free from tradeoffs. The relevant question is not whether vaccines “work,” but how, for whom, under what conditions, and at what cost. Those questions are scientific, not ideological.
Utility Does Not Imply Perfection
Vaccines differ substantially in their mechanisms, durability, and effectiveness in optimizing outcomes. Some vaccines confer near-sterilizing immunity with long-lasting protection, while others primarily reduce disease severity rather than infection risk. Seasonal influenza vaccines illustrate this distinction clearly. Vaccine effectiveness against infection commonly ranges between 30% and 60% across networks in recent seasons, with significant variability by year, viral subtype, and age group (Frutos et al., 2025). Despite this variability, influenza vaccines consistently reduce hospitalizations, intensive care admissions, and mortality, particularly among older adults and individuals with chronic diseases (Frutos et al., 2025). These benefits are meaningful, but they are not equivalent to comprehensive infection prevention. Treating partial effectiveness as either failure or perfection reflects the same conceptual error: misunderstanding what the intervention was designed to do.
Natural Immunity as a Legitimate Consideration
Natural immunity is not a myth, nor is it a talking point against vaccines. It is, however, a biologically documented phenomenon. Infection-acquired immunity can generate broad and durable immune responses, often involving mucosal immunity, memory B cells, and T-cell responses that differ qualitatively from those induced by vaccines. In some cases, particularly for respiratory viruses, prior infection significantly shapes subsequent immune responses to both infection and vaccination. Ignoring natural immunity does not strengthen science. It weakens it by omitting a strong and known variable from the risk assessment. The relevant question is not whether natural immunity exists, but how it compares with, complements, or conflicts with vaccine-induced immunity across populations and time horizons. Risk-informed decision-making requires acknowledging both.
Repeated Vaccination and Immune Complexity
Repeated vaccination introduces additional complexity. A substantial body of literature examines whether prior-season influenza vaccination attenuates measured vaccine effectiveness in subsequent seasons. A systematic review and meta-analysis in The Lancet Respiratory Medicine found that prior vaccination can reduce measured effectiveness in some seasons and subtypes, particularly influenza A(H3N2), while still offering better protection than no vaccination (Jones-Gray et al., 2023). Mechanistically, this phenomenon is often discussed in terms of immune imprinting, where early antigenic exposures bias subsequent antibody responses. Studies in Clinical Infectious Diseases demonstrate that preexisting antibody landscapes influence both the quantity and quality of vaccine responses (Kosikova et al., 2018). Granted, these findings do not contradict the argument for vaccination. Instead, they argue against linear assumptions about immune response and cumulative benefit.
Hyporesponsiveness and Vaccine-Specific Limitations
It must be made abundantly clear that not all vaccines behave the same immunologically. Certain polysaccharide vaccines exhibit immunologic hyporesponsiveness, a phenomenon in which repeated dosing diminishes antibody responses rather than amplifying them. This has been documented for meningococcal and pneumococcal polysaccharide vaccines (Richmond et al., 2000; Jokhdar et al., 2004). The development of conjugate vaccines was partly a response to this limitation. By engaging T-cell-dependent pathways, conjugate vaccines generate more robust immune memory. And yes, reviews in Expert Review of Vaccines emphasize that hyporesponsiveness is antigen- and formulation-specific, not a generalized vaccine failure (Poolman, 2011). This distinction here matters because outcomes matter. The point is that “vaccines” are not a single technology, and their risks and benefits cannot be discussed as if they were.
High-Risk Populations Versus the General Population
Public health recommendations often apply broadly, but the strongest evidence of benefit typically focuses on high-risk populations. This is a bad idea. For influenza, these include older adults, young children, pregnant individuals, and those with chronic cardiopulmonary, metabolic, or immunologic conditions (Frutos et al., 2025; World Health Organization, 2022). For healthy working-age adults and children without comorbidities, the baseline risk of severe disease is low. As a result, absolute risk reduction is smaller, even when relative risk reduction appears favorable. This does not mean vaccination lacks value for these groups, but it absolutely means that the benefit-risk profile differs. The problem here is that collapsing high-risk and general populations into a single narrative obscures meaningful differences and undermines informed consent.
Contrastive Inquiry: Conditions for Overestimation in Universal Recommendations
Universal recommendations may overestimate individual benefit for low-risk groups under specific conditions. These include seasons with poor antigenic match between vaccine strains and circulating viruses, where relative VE against infection drops below 40% and absolute reductions in mild outcomes become negligible given low baseline incidence. Of course, another condition arises when repeated vaccination interacts with imprinting, yielding attenuated responses in healthy adults repeatedly exposed to similar antigens. And finally, in populations with high rates of prior natural infection, hybrid immunity may already provide substantial protection against severe disease, diminishing incremental vaccine benefit. These scenarios show the complexity of individual absolute gain compared with broad policies, warranting stratified communication.
Non-Specific Effects and Why Hints Matter
It should be understood that vaccines can influence immune function beyond their target pathogens. Research on non-specific effects suggests that some vaccines may alter susceptibility to unrelated infections through mechanisms such as trained immunity, which involves the epigenetic and metabolic reprogramming of innate immune cells (Uthayakumar et al., 2018). Much of this evidence arises from observational studies in high-mortality settings and remains heterogeneous. However, hints matter in science. Even patterns matter. Epidemiology matters. Granted, observational signals are not proof, but they are the starting point for hypothesis generation. So suppressing such queries is not helpful. Reviews in Seminars in Immunology and Drug Safety argue that non-specific effects deserve systematic measurement rather than rhetorical dismissal (Benn et al., 2023). That said, I should be blunt: suppressing inquiry because the results are inconvenient is not scientific rigor.
Questioning Harm Is Not Anti-Science
One of the most corrosive developments in modern scientific culture is the framing of harm-related questions as inherently “controversial.” Questioning potential harm is not opposition to science. If anything, it is the definition of science. Every major advance in safety, from pharmacovigilance to post-marketing surveillance, exists because people investigated harms rather than denied them. If a good idea requires suppressing questions to survive, it is likely not a good idea. Robust interventions withstand scrutiny. They do not depend on social pressure, agenda, or moral framing to maintain legitimacy.
The Autism Question and Scientific Persistence
The vaccine–autism debate exemplifies this tension. Large epidemiological studies have not yet demonstrated a causal relationship between routine childhood vaccination and autism spectrum disorder. At the same time, more than two hundred peer-reviewed papers explore hypotheses linking immune activation, neurodevelopment, maternal inflammation, adjuvants, and timing-related vulnerabilities. This literature does not establish causation, but it does show scientific interest while demonstrating potential. At the same time, there is a strong effort to avoid looking.
In the interim, we should remember that the absence of evidence is not evidence of absence. Many studies investigate immune dysregulation rather than vaccines as a monolithic exposure. Curated bibliographies compiling this work illustrate the scope of inquiry rather than a settled conclusion. Scientific consensus reflects current weight of evidence, not permanent closure. Inquiry continues because biology is complex, observations continue, and the matter remains unsettled. Moreover, new and emerging technologies merely complicate the matter.
The Amyloid Question and Hints of Bigger Problems
Emerging research suggests that the spike protein, central to mRNA-based COVID-19 vaccines and viral infection, may induce amyloid-like microclot formation in certain individuals. In vitro experiments show that spike protein-derived peptides can self-assemble into amyloid fibrils, incorporate fibrinogen, and produce fibrinolysis-resistant clots that may contribute to thromboinflammatory states (Nyström & Hammarström, 2022; Rubther et al., 2024). Persistence of spike protein in monocytes for months post-vaccination further suggests possible prolonged vascular and immune impacts, especially in those with post-acute sequelae (Patterson et al., 2023). Observations in long COVID patients demonstrate elevated microclot levels associated with neutrophil extracellular traps; the identical structure of vaccine-encoded spike protein to the viral counterpart warrants exploration of whether vaccination could exacerbate such mechanisms in vulnerable populations (Thierry et al., 2025).
As physician Mary Talley Bowden (2026) stated on X, “Amyloid will be an important word in 2026. Amyloid is abnormal, insoluble protein that deposits in tissue and disrupts function. Spike protein – from both the virus and the mRNA shots – causes amyloid production. Removing amyloid is very difficult“. Indeed, these correlative findings, while preliminary, suggest potential broader consequences, such as prion-like protein misfolding or roles in autoimmunity and oncogenesis. This suggests that persistent spike expression might drive sustained microvascular obstruction and immune dysregulation, necessitating caution and longitudinal studies to assess vaccine safety across populations and identify biomarkers like amyloid-resistant microclots for risk mitigation.
Science Does Not Advance by Consensus
Questions still remain, and new discoveries muddy the waters. Regardless, consensus is a sociological outcome, not a scientific method. Science advances through evidence, replication, falsification, and refinement. Consensus can summarize the current state of knowledge, but it does not replace mechanistic understanding or eliminate uncertainty. History repeatedly demonstrates that consensus shifts as new data emerge. However, I am arguing that new data can emerge only if science is willing and able to ask the right questions and explore thoroughly. Appealing to consensus may be appropriate for policy, but it is insufficient for education and discovery. Scientific thinking requires understanding why conclusions are held, what assumptions support them, and where uncertainty remains.
Conclusion
Vaccines are neither flawless nor fraudulent. They are imperfect tools deployed in complex biological systems and imperfect social environments. Their benefits are real in some cases, particularly for high-risk populations; however, these benefits are not uniform, absolute, or immune to diminishing returns under certain conditions. This statement should not be controversial to any scientifically minded person. Scientific integrity requires acknowledging natural immunity, vaccine heterogeneity, population stratification, and unresolved questions without collapsing into denial or dogma. And finally, understand that rejecting false certainty is not anti-science. If anything, it is fidelity to how science actually works. Thank you for your time.
Dr. Robertson is a health researcher and educator, not a physician. The information provided here is not medical advice, a professional diagnosis, opinion, treatment, or service to you or any other individual. The information provided is for educational and anecdotal purposes only and is not a substitute for medical or professional care. You should not use this information as a substitute for a visit, call, consultation, or the advice of your physician or other healthcare providers. Dr. Robertson is not liable or responsible for any advice, course of treatment, diagnosis, or additional information, services, or products you obtain or utilize. IF YOU BELIEVE YOU HAVE A MEDICAL EMERGENCY, YOU SHOULD IMMEDIATELY CALL 911 OR YOUR PHYSICIAN.
Find value in this article? You may enjoy Sharyl Attkisson’s Links to Vaccine and Other Medical Stories.
References
Benn, C. S., Fisker, A. B., Rieckmann, A., & Sørup, S. (2023). Implications of non-specific effects for testing, approving, and regulating vaccines. Drug Safety, 46(6), 533–544. https://doi.org/10.1007/s40264-023-01295-3
Bowden, M. T. [@MaryBowdenMD]. (2026, January 1). Amyloid will be an important word in 2026. Amyloid is abnormal, insoluble protein that deposits in tissue and disrupts function. Spike protein – from both the virus and the mRNA shots – causes amyloid production. Removing amyloid is very difficult. I interviewed someone who has found a way – link in comments [Image attached]. X. https://x.com/MaryBowdenMD/status/2006747972948664413
Frutos, A. M., Cleary, S., Reeves, E. L., & CDC Influenza Vaccine Effectiveness Collaborators. (2025). Interim estimates of 2024–2025 seasonal influenza vaccine effectiveness—Four vaccine effectiveness networks, United States, October 2024–February 2025. MMWR Morbidity and Mortality Weekly Report, 74, 83–90. https://dx.doi.org/10.15585/mmwr.mm7406a2
Jokhdar, H., Borrow, R., Sultan, A., Adi, M., Riley, C., & Fuller, E. (2004). Immunologic hyporesponsiveness to serogroup C but not serogroup A following repeated meningococcal A/C polysaccharide vaccination. Clinical and Diagnostic Laboratory Immunology, 11(1), 83–88. https://doi.org/10.1128/CDLI.11.1.83-88.2004
Jones-Gray, E., Robinson, E. J., Kucharski, A. J., Fox, A., & Sullivan, S. G. (2023). Does repeated influenza vaccination attenuate effectiveness? A systematic review and meta-analysis. The Lancet Respiratory Medicine, 11(1), 27–44. https://doi.org/10.1016/S2213-2600(22)00338-6
Kosikova, M., et al. (2018). Imprinting of repeated influenza A/H3 exposures on antibody quantity and antibody quality. Clinical Infectious Diseases, 67(1), 152–160. https://doi.org/10.1093/cid/ciy327
Nyström, S., & Hammarström, P. (2022). Amyloidogenesis of SARS-CoV-2 spike protein. Journal of the American Chemical Society, 144(20), 8945–8951. https://doi.org/10.1021/jacs.2c03925
Patterson, B. K., Francisco, E. B., Yogendra, R., Long, E., Pise, A., Rodrigues, H., Hall, E., Herrera, M., Parikh, P., Guevara-Coto, J., Triche, T. J., Scott, P., Herrera, R., Banderas, M., & Kincaid, J. (2023). Persistence of SARS-CoV-2 S1 protein in CD16+ monocytes in post-acute sequelae of COVID-19 (PASC) up to 15 months post-infection. Frontiers in Immunology, 13, Article 1054372. https://doi.org/10.3389/fimmu.2022.1054372
Poolman, J. (2011). Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. Expert Review of Vaccines, 10(3), 307–322. https://doi.org/10.1586/erv.11.8
Richmond, P., Borrow, R., Goldblatt, D., Findlow, J., Martin, S., Morris, R., & Cartwright, K. (2000). Ability of meningococcal serogroup C conjugate vaccine to overcome immunologic hyporesponsiveness induced by previous administration of polysaccharide vaccine. Journal of Infectious Diseases, 181(2), 761–764. https://doi.org/10.1086/315284
Rubther, L., Wenzel, F., Grässle, S., Viereck, J., Schmidt, K., & Stangl, V. (2024). SARS-CoV-2 spike protein induces amyloid-like fibril formation in vitro and in vivo. Biomedicines, 12(8), Article 1765. https://doi.org/10.3390/biomedicines12081765
Thierry, A. R., Pretorius, E., & Kell, D. B. (2025). Circulating microclots are structurally associated with neutrophil extracellular traps and their amounts are elevated in long COVID patients. Journal of Medical Virology, 97(10), e70245. https://doi.org/10.1002/jmv.70245
Uthayakumar, D., Paris, S., Chapat, L., Freyburger, L., Poulet, H., & De Luca, K. (2018). Non-specific effects of vaccines illustrated through the BCG example. Seminars in Immunology, 39, 1–10. https://doi.org/10.1016/j.smim.2018.06.002
World Health Organization. (2022). Vaccines against influenza: WHO position paper – May 2022. Weekly Epidemiological Record, 97(19), 185–208. https://www.who.int/publications/i/item/who-wer9719
